Advertisement

Topics

Immunogenic Peptides (Vaccines) for the Treatment of Prostate and Breast Cancer

19:00 EST 31 Dec 2004 | NIH

Collectively, cancer is the second leading cause of death in the United States. Current treatments of cancer often involve non-specific strategies (such as chemotherapy) which attack healthy cells as well as diseased cells, leading to harmful side-effects. As a result, the development of more targeted means of treating cancer are highly sought after. One option for a targeted treatment is the creation of a vaccine that induces an immune response only against cancer cells. In this sense, vaccination involves the introduction of a peptide into a patient that causes the formation of T cells that recognize the peptide. If the recognized peptide found is found selectively on cancer cells, T cells can trigger the death of those cancer cells without harming non-cancer cells. This can result in fewer side effects for the patient.

TARP (T cell receptor gamma alternate reading frame protein) is a protein that is selectively expressed on the cells of certain types of prostate and breast cancer. This invention concerns the identification of two synthetic 9-mer TARP peptides, and their use to create an anti-cancer immune response in patients. By introducing these peptides as a vaccine into a patient, an immune response against these cancer cells can be initiated by the peptides, resulting in treatment of the cancer.

Note: This invention is a component of the multi-epitope TARP vaccine (E-047-2014) that is now in Clinical Phase II. The Phase I study was completed and published.

IC: 
NCI
NIH Ref. No.: 
E-116-2003/0
Advantages: 
  • Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients.
Applications: 
  • Peptides can be used as cancer vaccines.
  • Treatment of any cancer associated with increased or preferential expression of TARP.
  • Specific diseases include breast cancer and prostate cancer.
Development Status: 
  • Pre-clinical
  • Clinical
  • In vivo data available (animal)
  • In vivo data available (human)
Provider Technology ID: 
920
Updated On: 
Oct 23, 2017
Date Published: 
Saturday, January 1, 2005
Provider Classifications: 
Publications: 
Patent Application: 
12/430,837
10/559,329
PCT/US2004/17574
60/476,467
Patent Authority: 
US
US
PCT
US
Patent Number: 
8,043,623
7,541,035
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
NCI
Inventor Lab URL: 
http://irp.nih.gov/pi/jay-berzofsky
http://irp.nih.gov/pi/ira-pastan
LPM FIrst Name: 
Ricquita
LPM Last Name: 
Pollard
LPM Address: 
9609 Medical Center Dr. Room 1E-530, MSC 9702 Courier Address: 9609 Medical Center Dr. Room 1E-530, MSC 9702 Rockville, MD 20850-970
LPM City: 
Rockville
LPM Zip: 
20850-9702
Inv Is lead: 
LPM State: 
MD
LPM Phone: 
240-276-5530
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
240-276-5504
DTDT Classification: 
Cancer
Therapeutics
Immunoconjugates
Gene Therapy
Vaccines
Cancer
Therapeutic (biologic)
Antibody
Biomarker
DTDT Description: 
Cancer
Cancer - Therapeutics
Cancer - Therapeutics - Immunoconjugates
Cancer - Therapeutics - Gene Therapy
Cancer - Therapeutics: Vaccines
Cancer
Therapeutic (biologic)
Antibody
Biomarker
Pat Filing Date: 
2009-04-27
2005-12-02
2004-06-02
2003-06-05
Patent Issue Date: 
2011-10-25
2009-06-02
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/27622067
https://www.ncbi.nlm.nih.gov/pubmed/18446790
https://www.ncbi.nlm.nih.gov/pubmed/15059918
Publication Caption: 
PMID 27622067
PMID 18446790
PMID 15059918
Publication Title: 

Wood LV, et al.

Epel M, et al.

Oh S, et al.

Application Term: 
Disease Area Term: 
Technology Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Researchers at the NCI seek licensing and/or co-development research collaborations for a prostate cancer vaccine targeting the TARP antigen that has completed phase I clinical trials. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov.

Related Patent Publish Date: 
1386914400
1418364000
1465448400
Related Patent Application: 

61/915,948

PCT/US2014/070144

15/102,996

Related Patent Authority: 
US
PCT
US
Related Invention: 
E-047-2014/0
E Number Only: 
E-116-2003
Inventor First Name: 
Jay
Sang-kon
Ira
Inventor Last Name: 
Berzofsky
Oh
Pastan

Original Article: Immunogenic Peptides (Vaccines) for the Treatment of Prostate and Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Immunogenic Peptides (Vaccines) for the Treatment of Prostate and Breast Cancer"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...